platform

medicine

Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine’s Chemistry42 AI platform for generative chemistry

Since the publication of Ian Goodfellow’s original paper on generative adversarial networks (GANs) in 2014, Insilico Medicine has been developing generative chemistry and generative biology algorithms. In 2016, Insilico Medicine published the first peer-reviewed publication describing the application of GANs to small molecule discovery in oncology. Between 2016 and 2020 Insilico Medicine authored over 40 papers and has been granted several patents in this field. Insilico Medicine has conducted several proof of concept validation experiments that demonstrate that generative models can successfully identify novel targets, and design molecules with desired properties that can be synthesized and tested in vitro and in vivo

Chemistry42™ is a core part of Insilico’s Pharma.ai drug discovery suite. It is a flexible, user-friendly software platform that bridges artificial intelligence (AI) and machine learning methods with domain expertise in the fields of medicinal and computational chemistry, for the design of novel small molecules with desirable physicochemical properties. The platform is a scalable distributed web application, capable of running multiple tasks in parallel in a matter of hours. Container orchestration and workflow management allow for predictable hardware-agnostic resource allocation, and for the implementation on either cloud or local HPC infrastructures.

We are very happy to have Merck KGaA, Darmstadt, Germany sign on as our very first launch partner as they have substantial experience in the field of AI-powered drug discovery internally and built a world-class computing infrastructure,” said Alex Zhavoronkov, PhD, founder, and CEO, Insilico Medicine.

“Chemistry42 v1.0 is the result of years of comprehensive research in generative chemistry, close collaboration between computational and medicinal chemistry scientists, and best high-performance computing engineering practices. We are excited to work closely with Merck KGaA, Darmstadt, Germany and look forward to demonstrating the impact of our collaboration on their drug discovery programs,” said Alex Zhebrak, PhD, CTO of Insilico Medicine.

“We’re excited to continue to deploy the latest tools in AI,” said Joern-Peter Halle, Global Head of Research for the Healthcare business sector of Merck KGaA, Darmstadt, Germany. “AI has the potential to transform the drug discovery process and Insilico Medicine is at the forefront of exciting AI techniques, such as this generative chemistry AI platform.”

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD

Read More
medicine

Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine’s Chemistry42 AI platform

IMAGE

IMAGE: Insilico announces the first launch partner for Chemistry42
view more 

Credit: Insilico

November 17, 2020, 9:00AM EST– Following the release of Chemistry42 to a select group of key experts in the pharmaceutical industry in Q3 2020, Insilico Medicine is proud to announce that Merck KGaA, Darmstadt, Germany will be the first launch partner for its flagship generative chemistry artificial intelligence (AI) platform – Chemistry42. Merck KGaA, Darmstadt, Germany will integrate Chemistry42™ into their discovery pipeline to facilitate rapid and effective drug design. Chemistry42 v1.0 will be customized and deployed on state-of-the-art high-performance computing (HPC) infrastructure at Merck KGaA, Darmstadt, Germany.

Since the publication of Ian Goodfellow’s original paper on generative adversarial networks (GANs) in 2014, Insilico Medicine has been developing generative chemistry and generative biology algorithms. In 2016, Insilico Medicine published the first peer-reviewed publication describing the application of GANs to small molecule discovery in oncology. Between 2016 and 2020 Insilico Medicine authored over 40 papers and has been granted several patents in this field. Insilico Medicine has conducted several proof of concept validation experiments that demonstrate that generative models can successfully identify novel targets, and design molecules with desired properties that can be synthesized and tested in vitro and in vivo.

Chemistry42™ is a core part of Insilico’s Pharma.ai drug discovery suite. It is a flexible, user-friendly software platform that bridges artificial intelligence (AI) and machine learning methods with domain expertise in the fields of medicinal and computational chemistry, for the design of novel small molecules with desirable physicochemical properties. The platform is a scalable distributed web application, capable of running multiple tasks in parallel in a matter of hours. Container orchestration and workflow management allow for predictable hardware-agnostic resource allocation, and for the implementation on either cloud or local HPC infrastructures.

We are very happy to have Merck KGaA, Darmstadt, Germany sign on as our very first launch partner as they have substantial experience in the field of AI-powered drug discovery internally and built a world-class computing infrastructure,” said Alex Zhavoronkov, PhD, founder, and CEO, Insilico Medicine.

Chemistry42 v1.0 is the result of years of comprehensive research in generative chemistry, close collaboration between computational and medicinal chemistry scientists, and best high-performance computing engineering practices. We are excited to work closely with Merck KGaA, Darmstadt, Germany and look forward to demonstrating the impact of our collaboration on their drug discovery programs,” said Alex Zhebrak, PhD, CTO of Insilico Medicine.

“We’re excited to continue to deploy the latest tools in AI,” said Joern-Peter Halle, Global Head of Research for the Healthcare business sector of Merck KGaA, Darmstadt, Germany. “AI has the potential to transform the drug discovery process and Insilico Medicine is at the forefront of exciting AI techniques, such as this generative chemistry AI platform.”

###

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s

Read More
medicine

Genialis Harnesses RNA-seq Platform to Advance Precision Medicine Discoveries

SAN RAMON, Calif.–(BUSINESS WIRE)–Genialis, a leader in applied data science for the development of precision medicines, will present a poster alongside OncXerna (fka Oncologie) at the upcoming Society for Immunotherapy of Cancer conference (SITC 2020). The poster, titled “Development of an RNA-based Diagnostic Platform Based on the Tumor Microenvironment Dominant Biology,” (Poster 257) will be discussed on Wednesday, November 11, and Friday, November 13, 2020.

The SITC presentation is the first scientific disclosure from the companies’ ongoing collaboration, previously announced in January 2020, to develop a state-of-the-art RNA-based biomarker platform, with this initial panel capturing the complexities of the tumor microenvironment. Today, 90 percent of patients do not have a precision medicine solution based on DNA profiling. Thorough characterization of RNA expression enables OncXerna’s panel to describe the cancer’s dominant biology to match patients to a drug whose MOA targets that biology. Genialis is optimizing algorithms for patient selection, a critical step towards developing a companion diagnostic for a given drug. The poster will highlight biomarker validations on approved therapies and application to OncXerna’s investigational clinical programs.

Genialis’ participation at SITC is the latest in a series of milestone achievements in the last two quarters of 2020, including ongoing engagements with biopharma collaborators; updates to its precision medicine software platform; and an addition to its board of directors. More information on each of these updates can be found below:

PRECISION MEDICINE COLLABORATIONS

Throughout 2020, Genialis’s industry partners have drawn from the company’s expertise in gene expression and genome regulation to develop or discover innovative new drugs across the R&D lifecycle, from target validation to translational modeling to clinical biomarkers. Of these diverse use cases, the last piece—biomarkers that predict drug response—remains a central focal point. These partners include growth-stage biotechs, including InhibRx, Elevar and Kronos, as well as various larger pharma with deep pipelines, to academic institutions like Baylor College of Medicine’s Therapeutic Innovation Center (THINC).

ANALYTICS SOFTWARE

Genialis has also recently released an update to its proprietary software features as part of the Expressions platform to include a formal pipeline to support the analysis of data generated by the Cut-and-Run method for DNA-protein binding. This is a tool increasingly used to study transcription factors and other chromatin modifiers. Other novel methods supported on Expressions include SLAM-seq, for dissecting transcriptional dynamics, and various permutations of CLIP-seq, for assaying transcriptional processing. Genialis and Roche are also currently co-promoting their unified solution for Roche’s KAPA RNA HyperPrep Kits.

PEOPLE NEWS

In Q3 2020, Nadine Geiser, Ph.D., joined the Board of Directors. Dr. Geiser is an investment manager at Redalpine Venture partners and takes over the firm’s seat on the board. She is a formally trained scientist, studied biotechnology in Munich, Germany and Singapore before completing a Ph.D. in proteomics at ETH Zurich, Switzerland. Previously Dr. Geiser worked in Amsterdam for a corporate venture firm and in the equity research department of an investment bank in Zurich before joining Redalpine in 2019.

“To realize the potential of precision medicine, we

Read More
medicine

Genialis Harnesses RNA-seq Platform to Advance Precision Medicine Discoveries – Press Release

SAN RAMON, Calif.–(Business Wire)–Genialis, a leader in applied data science for the development of precision medicines, will present a poster alongside OncXerna (fka Oncologie) at the upcoming Society for Immunotherapy of Cancer conference (SITC 2020). The poster, titled “Development of an RNA-based Diagnostic Platform Based on the Tumor Microenvironment Dominant Biology,” (Poster 257) will be discussed on Wednesday, November 11, and Friday, November 13, 2020.

The SITC presentation is the first scientific disclosure from the companies’ ongoing collaboration, previously announced in January 2020, to develop a state-of-the-art RNA-based biomarker platform, with this initial panel capturing the complexities of the tumor microenvironment. Today, 90 percent of patients do not have a precision medicine solution based on DNA profiling. Thorough characterization of RNA expression enables OncXerna’s panel to describe the cancer’s dominant biology to match patients to a drug whose MOA targets that biology. Genialis is optimizing algorithms for patient selection, a critical step towards developing a companion diagnostic for a given drug. The poster will highlight biomarker validations on approved therapies and application to OncXerna’s investigational clinical programs.

Genialis’ participation at SITC is the latest in a series of milestone achievements in the last two quarters of 2020, including ongoing engagements with biopharma collaborators; updates to its precision medicine software platform; and an addition to its board of directors. More information on each of these updates can be found below:

PRECISION MEDICINE COLLABORATIONS

Throughout 2020, Genialis’s industry partners have drawn from the company’s expertise in gene expression and genome regulation to develop or discover innovative new drugs across the R&D lifecycle, from target validation to translational modeling to clinical biomarkers. Of these diverse use cases, the last piece—biomarkers that predict drug response—remains a central focal point. These partners include growth-stage biotechs, including InhibRx, Elevar and Kronos, as well as various larger pharma with deep pipelines, to academic institutions like Baylor College of Medicine’s Therapeutic Innovation Center (THINC).

ANALYTICS SOFTWARE

Genialis has also recently released an update to its proprietary software features as part of the Expressions platform to include a formal pipeline to support the analysis of data generated by the Cut-and-Run method for DNA-protein binding. This is a tool increasingly used to study transcription factors and other chromatin modifiers. Other novel methods supported on Expressions include SLAM-seq, for dissecting transcriptional dynamics, and various permutations of CLIP-seq, for assaying transcriptional processing. Genialis and Roche are also currently co-promoting their unified solution for Roche’s KAPA RNA HyperPrep Kits.

PEOPLE NEWS

In Q3 2020, Nadine Geiser, Ph.D., joined the Board of Directors. Dr. Geiser is an investment manager at Redalpine Venture partners and takes over the firm’s seat on the board. She is a formally trained scientist, studied biotechnology in Munich, Germany and Singapore before completing a Ph.D. in proteomics at ETH Zurich, Switzerland. Previously Dr. Geiser worked in Amsterdam for a corporate venture firm and in the equity research department of an investment bank in Zurich before joining Redalpine in 2019.

“To realize the potential of precision medicine, we need to better

Read More
medicine

Kerala Govt Allows Covid-19 Outpatient Services Under Tele-medicine Platform

As coronavirus is yet to be contained completely, people can now avail themselves of COVID-19 outpatient services through a tele-medicine platform e-Sanjeevani. People, suffering from the virus infection, and those with post-COVID-19 syndrome can use the service, state Health Minister K K Shylaja said here on Monday.

It is essential to seek treatment either directly or through the e-sanjeevani if any related health problem is found in those recovered from the coronavirus. “The OP service is available daily between 9 am and 5 pm via e-sanjeevani outpatient department. Those suffering from any health issues even after getting rid of the infection should make maximum use of this platform and seek expert treatment,” she said.

It would be a great help not only for those suffering from the disease but also for those who are tested negative for the infection and those suspecting to have infected with the coronavirus, she said. Virtual screening, treatment and reference are possible through the platform.

Specially-trained doctors are conducting the OPs. Stating that post-COVID syndrome is one of the most important issues when it comes to the impact of the infection, the Minister said the state Health Department had already opened post-COVID-19 syndrome clinics in hospitals.

“However, many still find it difficult to go directly to the hospitals. That’s why the OP clinics are opened through the e-sanjeevani platform also,” Shylaja added. e-sanjeevani is a consultation platform that allows people to get treatment without having to go hospitals during the time of the pandemic.

It helps people to avoid unnecessary hospital visits during the COVID-19 pandemic and thereby ensure expert treatment at home. The state government hadbecome part of the e-Sanjeevani as asustainable solution for non-COVID-19 patient care while avoiding direct interface with doctors during the COVID-19 crisis.

Developed by the Centre for Development of Advanced Computing (CDAC), the app, offering high-utility features, was launched on June 10.

Source Article

Read More
medicine

Now, OP service through tele-medicine platform

Thiruvananthapuram, Nov 9 (PTI):As coronavirus is yet to be contained completely, people can now avail themselves of COVID-19 outpatient services through a tele-medicine platform e-Sanjeevani.

People, suffering from the virus infection, and those with post-COVID-19 syndrome can use the service, state Health Minister K K Shylaja said here on Monday.

It is essential to seek treatment either directly or through the e-sanjeevani if any related health problem is found in those recovered from the coronavirus.

‘The OP service is available daily between 9 am and 5 pm via e-sanjeevani outpatient department. Those suffering from any health issues even after getting rid of the infection should make maximum use of this platformand seek expert treatment,’ she said.

It would be a great help not only for those suffering from the disease but also for those who are tested negative for the infection and those suspecting to have infected with the coronavirus, she said.

Virtual screening, treatment and reference are possible through the platform.

Specially-trained doctors are conducting the OPs.

Stating that post-COVID syndrome is one of the most important issues when it comes to the impact of the infection, the Minister said the state Health Department had already opened post-COVID-19 syndrome clinics in hospitals.

‘However, many still find it difficult to go directly to the hospitals. That’s why the OP clinics are opened through the e-sanjeevani platform also,’ Shylaja added.

e-sanjeevani is a consultation platform that allows people to get treatment without having to go hospitals during the time of the pandemic.

It helps people to avoid unnecessary hospital visits during the COVID-19 pandemic and thereby ensure expert treatment at home.

The state government hadbecome part of the e-Sanjeevani as asustainable solution for non-COVID-19 patient care while avoiding direct interface with doctors during the COVID-19 crisis.

Developed by the Centre for Development of Advanced Computing (CDAC), the app, offering high-utility features, was launched on June 10. PTI LGK NVG NVG

Source Article

Read More
fitness

Health and Fitness Visionary Dr. Jeremy James Launches The FITFOREVER Platform

This article was produced in partnership with T1.



a young man riding a skateboard down the side of a mountain: .


© Provided by Men’s Journal
.

As 2020 has indeed proven to be an unrelenting year of challenges as a result of the coronavirus pandemic, government mandated quarantines, the economic collapse, and more, now more than ever, Americans are realizing the importance of maintaining a healthy and fit lifestyle. While the year has forced many business owners to reevaluate their companies and businesses, Colorado-based health and fitness visionary, Dr. Jeremy James saw the disadvantages of 2020 as an opportunity to reexamine how he could help optimize the performance and physical activity of Americans everywhere and recognized the demand for a safe and effective exercise program that people could utilize at home. With this, he developed FITFOREVER, the first of its kind, digital fitness platform that is completely customized to a user’s body and can be performed from home.

Loading...

Load Error

As many might have realized during quarantine, the current landscape for digital fitness programs revealed how most approaches enlist a one-size-fits-all style of for training. Though it may work for some, for others, an approach like this often leads to injuries and inefficient workouts. In light of this realization, Dr. James along with his team of health and medical experts designed FITFOREVER to serve its users with a personalized fitness program that meets their needs, abilities, goals, and equipment availability.

With an extensive background in chronic back pain and human biomechanics, Dr. James is known for his best-selling book The Younger Next Year Back Book as well as two other programs, BACKFOREVER and GOLFFOREVER. After designing these two programs as a way to help people regain mobility and retrain the body to move freely without pain in the back or body, Dr. James saw huge success rates within his client base. With the foundation of his two prior programs, the fitness expert parlayed this expertise into FITFOREVER, with its focus being a comprehensive digital fitness platform that ranks helping users feel great as a top priority.

“Our method is simple,” says Dr. James. “At FITFOREVER, our focus is on building a highly functional body that feels great. Looking good is just a wonderful side effect.”

Through a personal assessment test, the program is the first of its kind, as it builds out a workout plan specifically designed to cater to each user’s body type, physical capabilities and goals. The program also takes into consideration things like pre-existing pain and injuries as well as the type of workout equipment a user has available to use. With daily-guided workout videos, users will enjoy their customized fitness plan as they begin their journey to building a strong foundation of physical activity and health, something Dr. James intends for all FITFOREVER members. While most existing digital fitness resources and platforms focus solely on aesthetic, FITFOREVER is one of the first to prioritize longevity and overall wellness.

“I saw a need to provide consumers with an educational foundation for greater mobility and healthy living,” says Dr. James.

Read More
fitness

Today In Retail: Fitness Platform Launches

In today’s top news in retail, fitness startup Moxie launches its platform, Amazon earnings are expected on Thursday (Oct. 29) and grocery giant Kroger said its “Restock Kroger” framework will generate shareholder returns of 8 to 11 percent.

Got Moxie? Fitness Startup Enables Trainers To Work From Home

Moxie launched Tuesday (Oct. 27) after spending the summer and fall in beta. Its CEO likes to call it the Airbnb of fitness. More formally, it is a hybrid fitness site for instructors to reach clients, both new and existing. And it’s a site where fitness enthusiasts can find subscriptions for monthly or weekly live classes, all streamed directly on its platform. Subscribers also get access to the video recordings, which can be streamed on Moxie’s site, as well as music clearances, playlists and CRM functionality for the instructors to manage their clients. During the beta phase, Goldberg says there were more than 6,500 classes available, and more than 10,000 individual sessions were live-streamed. The site has also signed up more than 2,000 instructors.

Amazon Earnings Could Produce First $100B Quarter

Amazon reports earnings on Thursday (Oct. 29) and it has an impossible act to follow. With its Q2 earnings reaping every benefit of the pandemic-driven digital-first economy, it set a new standard for exploding past earnings estimates with revenue up 40 percent to $88.9 billion. While it’s a safe bet that Amazon will beat estimates, it won’t come close to the Q2 performance. But as the retail world waits to see what is expected to be a record-setting quarter for Amazon, there are some key indicators to watch. The company has already level set expectations when it said in July that it expects Q3 net sales to come in at between $87 billion and $93 billion, which would be a year-over-year growth rate of between 24 to 33 percent.

Kroger Bullish On Earnings As Supermarket Giant Takes On Digital World

Kroger Co. “has reinvented the company’s business model to deliver consistently strong and attractive total shareholder return,” the company said in a press release on Tuesday (Oct. 27). The Cincinnati-based supermarket giant said its “Restock Kroger” framework will generate shareholder returns of 8 to 11 percent. Restock Kroger is the company’s program to improve shipping, distribution and the links between its online and offline businesses. The company made “several strategic decisions three years ago” to better service its customers, Kroger Chairman and CEO Rodney McMullen said in the release. “We believed customers would continue to move to a seamless shopping platform that combined the best of physical and digital experiences. These choices and investments have positioned Kroger to more effectively respond to the pandemic,” he said.

——————————

NEW PYMNTS DATA: HOW WE SHOP – SEPTEMBER 2020 

The How We Shop Report, a PYMNTS collaboration with PayPal, aims to understand how consumers of all ages and incomes are shifting to shopping and paying online in the midst of the COVID-19 pandemic. Our research builds

Read More
fitness

Fit4Mii app Announces Online and Online-to-offline Fitness Training Platform and Multi-Lingual Marketplace

“Find the right fit for you at Fit4Mii”

In one swift move, Fit4Mii app has established a workout system that allows fitness enthusiasts to participate virtually via the internet or offline from it’s world-class trainers. The platform also features a marketplace where fitness enthusiasts can get their hands on all necessary tools required to achieve a healthy body and mind.

Fit4Mii app is a fully accessible online and online-to-offline fitness platform and market place. It provides online training for everyone, no matter age or ability both on and offline. Fit4Mii app trainers go through rigorous training and are largely multi-lingual and when combined, speak 19 languages. They are qualified in many disciplines including Muay Thai, corrective exercise, yoga, nutrition, pilates, and Zumba. At Fit4Mii app, there is an online fitness class for everyone, everywhere regardless of age, language, health condition, body type and gender.

Given the covid pandemic, health and fitness has become an important focus. Physical fitness is generally achieved through proper nutrition, moderate to vigorous physical exercise, and sufficient rest. The Fit4Mii app online fitness platform does not only help users to exercise, but to do it the right way. Fit4Mii app enables each participant to find tailored fitness programs to help them get the most from working out. Besides fitness, these programs also touch on other aspects of health and wellness such as bone, mental, social and emotional.

Fit4Mii app has a well-rounded online fitness program to improve a person’s fitness levels in all aspects of fitness. Fitness enthusiasts have come forward to say that the platform has been a lot of help as it has pushed them into developing other parts of their bodies. Without Fit4Mii app, most participants confessed to only practicing cardio/respiratory endurance or weight training.

Fit4Mii app is virtual gym providing live and interactive fitness classes online. Participants can access several fitness courses or programs ranging from Cardio, Dance, Nutrition to Kids fitness, and Family. In a bid to make its services available to everyone, the team at Fit4Mii has made sure to mix its paid courses with some free courses. Now, everyone can participate.

For more information visit the Fit4Mii website or use the media contact outlets below.

Media Contact
Company Name: Fit4Mii app
Contact Person: C.king
Email: Send Email
Address:Reurikwei 62
City: Arnhem
State: Gelderland
Country: Netherlands
Website: https://www.fit4miiapp.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fit4Mii app Announces Online and Online-to-offline Fitness Training Platform and Multi-Lingual Marketplace

Source Article

Read More
health

GoodCell Raises $17.9 Million to Accelerate Development of Its Actionable Health Technology Platform

Capital will fuel continued growth of the company’s IP for measuring genetic variations in cells and scaling its cutting-edge data and analytics platform to track, monitor and support identification of potential health risks

GoodCell (“LifeVault Bio”), the company decoding human health to extend and improve the quality of life through technology powered by science, today announced that it has raised $17.9 million in a preferred equity round. GoodCell intends to use this latest funding to support the company’s IP for detecting and monitoring accumulated genetic variation within blood cells. Financing will also help advance the company’s big data analytics platform to validate novel applications for its health tracking and risk identification solutions through GoodCell Diagnostics and GoodCell’s personal biobanking service.

“COVID-19 has demonstrated the importance of solutions that can help people understand their risks and stay ahead of their health,” said Trevor Perry, Founder and Chief Executive Officer, GoodCell. “We are grateful for a growing investor community that shares our passion for delivering on the promise of personalized healthcare. This latest capital infusion will help us achieve our next stage of development for our platform as we introduce new solutions to the market that change the way individuals, researchers, clinicians and pharmacists predict, identify and monitor disease risk.”

Inherited genetic predisposition to disease has become a fixture of research and clinical care. However, accumulated, or somatic, genetic variations that emerge as a result of age and environmental factors remain a relatively underexplored area of study. A growing body of research suggests that accumulated genetic variations that culminate in the expansion of detrimental variations and cause damage to DNA within blood cells – a phenomenon known as clonal hematopoiesis (CH) – may be linked to higher disease risk. Notably, research continues to bolster linkages between these somatic changes and the aberrant immune response associated with severe COVID-19 cases. These variations have also been correlated to a predisposition toward certain cancers and cardiovascular conditions.

GoodCell, which recently filed patent applications for methods of predicting susceptibility to infectious disease and related methods of treatment, uniquely measures and monitors both inherited and acquired genetic variations in blood stem cells and other nucleated cells in blood over time. Proceeds from this latest raise will support the ongoing buildout of the company’s proprietary data aggregation and analytics technology platform, which aims to decode our cells and harness their insights to advance population and personal health. The funding is also intended to support exploration and development of novel applications for these data streams to support emerging science as it relates to pathogen susceptibility, cell quality, autoimmune and inflammatory disease assessment and more.

Notably, the company’s latest filings informed the development of the GoodCell Pathogen Susceptibility Testing Platform and serve as the foundation for a recently launched three-stage study to investigate COVID-19 in collaboration with New York Blood Center. The resulting research, anticipated in the coming months, is expected to provide important data on COVID-19 risk factors that could ultimately inform the creation of a first-of-its-kind susceptibility test

Read More